ly011
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2021 (NCT04966143)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Claudin-18Immunity, passive
CLDN18 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04977193 | Early Phase 1 (Phase 1) | Nov 1, 2021 | Shanghai Longyao Biotechnology Inc., Ltd., Xuzhou Medical University |
| NCT04966143 | Early Phase 1 (Phase 1) | Aug 1, 2021 | Shanghai Longyao Biotechnology Inc., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Longyao Biotechnology Inc., Ltd. | Government | 2 | 2 | 1 | 2021 |
| Xuzhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1